NEWS DETAIL

FDAは、標的療法が適用できない急性骨髄性白血病患者に対し、デシタビン/シダザロリドとベネトクラクスの併用療法を承認した – Targeted Oncology

米国食品医薬品局(FDA)は、標的がん治療の適応とならない急性骨髄性白血病患者に対し、デシタビン/シダザロリドとベネトクラクスの併用療法を承認した。

医療情報

该文章暂未提取到完整正文,已从资讯列表和商品关联资讯中自动隐藏。你可以返回文章列表继续浏览其他内容。

Products Mentioned in This Article

These products were automatically matched from the article title, summary, and full content.

Frequently Asked Questions

Which products are related to this article?

The system matched these relevant products from the article content: Lucius Quizartinib – Buy Online、Lucius Anagrelide – Buy Online、Lucius Tazemetostat – Buy online、Lucius Acalabrutinib – Buy Online.

How can I view the medicines discussed in this article?

Use the related product cards below the article to review available specifications, prices, product information, and reviews.

Does this article replace advice from a doctor or pharmacist?

No. This content is for general information and health education only. Follow the prescription and individual guidance provided by qualified healthcare professionals.

WhatsApp WhatsApp WeChat WeChat